Sulfuric acid magnesium salt (1:1) → 7-[(3aS,4R,6R,6aR)-6-({[(3-{[6-chloro-5-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]methyl}cyclobutyl)methyl](propan-2-yl)amino]methyl)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
反応式
[Cl:1][C:2]1[C:3]([C:26]([F:29])([F:28])[F:27])=[CH:4][C:5]2[N:9]=[C:8]([CH2:10][CH:11]3[CH2:14][CH:13]([CH:15]=O)[CH2:12]3)[N:7]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:24])([CH3:23])[CH3:22])[C:6]=2[CH:25]=1.[CH3:30][C:31]1([CH3:54])[O:35][C@@H:34]2[C@@H:36]([CH2:49][NH:50][CH:51]([CH3:53])[CH3:52])[CH2:37][C@@H:38]([N:39]3[C:43]4[N:44]=[CH:45][N:46]=[C:47]([NH2:48])[C:42]=4[CH:41]=[CH:40]3)[C@@H:33]2[O:32]1.[O-]S([O-])(=O)=O.[Mg+2].C([O-])(O)=O.[Na+]>ClCCCl.[Cl-].[Na+].O>[Cl:1][C:2]1[C:3]([C:26]([F:29])([F:27])[F:28])=[CH:4][C:5]2[N:9]=[C:8]([CH2:10][CH:11]3[CH2:12][CH:13]([CH2:15][N:50]([CH2:49][C@@H:36]4[C@H:34]5[O:35][C:31]([CH3:54])([CH3:30])[O:32][C@H:33]5[C@H:38]([N:39]5[C:43]6[N:44]=[CH:45][N:46]=[C:47]([NH2:48])[C:42]=6[CH:41]=[CH:40]5)[CH2:37]4)[CH:51]([CH3:52])[CH3:53])[CH2:14]3)[N:7]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:24])([CH3:22])[CH3:23])[C:6]=2[CH:25]=1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
A solution of 3-{[6-chloro-5-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]methyl}cyclobutane-1-carbaldehyde (223 mg, 0.50 mmol), 7-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-[(propan-2-ylamino)methyl]-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (172 mg, 0.50 mmol) and MgSO4 (600 mg, 5.00 mmol) in DCE (10 ml) was stirred for 15 min. STAB (148 mg, 0.70 mmol) was then added to the reaction mixture and stirred for 1 h at RT. The reaction was monitored by LCMS, no amine was seen after 2.5 h. Sat. NaHCO3 (20 ml) was added to the reaction mixture and stirred for 5 mins. Brine (20 ml) was then added to the reaction mixture. The product was extracted with DCM (2×30 ml), dried over Na2SO4, filtered and evaporated. Purification by prep. HPLC gave the desired product (174 mg, 45%) as a white solid; MS (ESI+) for C38H53ClF3N7O3Si m/z 776.30 [M+H]+; HPLC purity 100% (ret. time, 1.68 min); 1H NMR (500 MHz, MeOD) δH ppm −0.25-0.11 (9H, m), 0.90 (2H, td, J=7.88, 3.47 Hz), 1.30 (3H, s), 1.37 (6H, t, J=7.49 Hz), 1.55 (3H, s), 1.63-1.84 (1H, m), 1.99-2.37 (2H, m), 2.37-3.03 (6H, m), 3.04-3.28 (3H, m), 3.34-3.50 (1H, m), 3.61 (2H, td, J=7.92, 2.29 Hz), 3.79 (1H, br. s.), 4.68 (1H, t, J=6.70 Hz), 4.95-5.27 (2H, m), 5.55-5.81 (1H, m), 6.88 (1H, d, J=3.63 Hz), 7.06-7.62 (2H, m), 7.61-7.94 (1H, m), 7.94-8.16 (1H, m), 8.22 (1H, s)
後処理
- additionSTAB (148 mg, 0.70 mmol) was then added to the reaction mixture
- stirringstirred for 5 mins
- extractionThe product was extracted with DCM (2×30 ml)
- dry with materialdried over Na2SO4
- filtrationfiltered
- customevaporated
- customPurification by prep
出典と根拠
- ORDレコード
- ord-6e9fa54457ab4bbd95016904395fe86d
- 出典データセット
- uspto-grants-2015_08
- 特許番号
- US09096634B2
反応ノート
読み込み中…